Anika Therapeutics Inc.

ANIK Healthcare Drug Manufacturers Specialty & Generic

Anika Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $112.8 million, down 5.91% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 189.3% and free cash flow grew 61.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

19.98 0.71 −3.43%
Market cap
$276.9M
P/E
0.0×
Fwd P/E
−20.0×
Dividend yield
—
F-score
6/9
Altman Z
3.13
Beneish M
−2.84
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
22.57 25.19 25.85 26.87 0.00 123.55 0.00 0.00 0.00 0.00
Piotroski F-Score
6 5 6 8 3 8 5 4 5 6
Altman Z-Score
27.60 27.39 21.49 12.90 5.55 6.96 5.76 5.12 4.52 3.13
P/S ratio
7.12 7.06 4.60 6.39 4.93 3.49 3.77 2.75 2.02 1.22
P/FCF ratio
70.51 25.14 16.04 21.42 56.28 158.57 0.00 0.00 0.00 27.77
Altman Z″-Score (non-manufacturers)
21.50 22.34 25.58 14.59 7.04 9.77 9.42 8.59 7.22 6.68
Beneish M-Score
(1.95) (2.85) (2.90) (2.32) (2.51) (2.23) (2.24) (3.11) (2.62) (2.84)
P/Operating CF
121.21 114.64 48.48 56.23 248.82 115.38 892.43 91.29 153.17 29.72
P/B ratio
3.30 3.04 1.84 2.54 2.36 1.80 1.50 1.56 1.57 0.96
Price to Tangible BV
3.58 3.27 1.97 2.68 3.72 2.62 2.11 1.64 1.68 1.03
EV/Sales
5.91 5.67 3.09 4.96 4.37 3.02 3.23 2.39 1.77 0.93
EV/EBITDA
11.24 12.86 11.96 14.13 14.72 18.61 20.26 3.73 38.61 0.00
EV/Operating CF
24.99 15.76 9.35 15.37 43.66 53.19 83.45 (161.28) 39.18 9.41
EV/FCF
58.56 20.20 10.79 16.64 49.87 137.25 (119.57) (39.97) (90.81) 21.22
Quick Ratio
17.32 13.85 15.93 12.78 3.32 4.17 4.33 3.06 3.40 3.71
Current Ratio
19.37 15.78 17.98 14.39 4.81 5.66 6.07 5.26 4.88 4.72
Net Debt/EBITDA
(2.30) (3.14) (5.83) (4.60) (2.54) (3.93) (4.75) (0.89) (10.15) 10.80
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.43 0.43 0.38 0.38 0.37 0.41 0.33 0.39 0.51 0.57
Operating CF/Net income
0.75 1.28 1.87 1.36 (0.54) 2.03 (0.30) 0.02 (0.10) (1.03)
Capex/Depreciation
(3.75) (2.09) (0.84) (0.47) (0.02) (0.24) (0.52) (0.07) (0.73) (1.09)
ROE
15.01% 13.09% 7.10% 9.85% (8.55%) 1.48% (5.19%) (33.21%) (30.79%) (7.32%)
ROA
13.68% 12.17% 6.67% 8.92% (6.89%) 1.16% (4.27%) (26.68%) (23.82%) (5.54%)
ROIC
32.27% 26.90% 13.00% 20.69% (10.17%) 0.85% 1.15% 0.37% (3.24%) (8.03%)
Return on Tangible Assets
15.21% 12.76% 7.62% 10.12% (12.55%) 2.22% (7.82%) (48.72%) (43.59%) (8.93%)
Average Days of Receivables
97.44 76.67 71.84 73.50 67.43 73.70 111.04 79.65 71.82 76.64
Research and Development Expense of Revenue
10.38% 16.56% 17.23% 14.54% 17.96% 18.49% 16.10% 18.02% 21.30% 22.84%
Selling, General and Administrative Expense of Revenue
17.42% 18.99% 32.53% 30.49% 46.04% 50.13% 45.01% 49.61% 46.33% 43.51%
Intangible Assets out of Total Assets
0.07 0.07 0.06 0.05 0.27 0.26 0.23 0.04 0.05 0.05
Share Based Compensation of Revenue
3.28% 5.12% 10.46% 5.31% 4.13% 7.50% 12.58% 12.62% 10.95% 8.94%
Graham Net Nets
0.21 0.23 0.39 0.26 0.13 0.21 0.25 0.32 0.27 0.41
Graham Number
27.53 29.78 23.11 29.78 0.00 11.41 0.00 0.00 0.00 0.00
Earnings Yield
4.43% 3.97% 3.87% 3.72% (3.72%) 0.81% (3.49%) (24.93%) (23.39%) (7.91%)
Free Cash Flow Yield
1.42% 3.98% 6.23% 4.67% 1.78% 0.63% (0.72%) (2.17%) (0.96%) 3.60%
Revenue per Share
7.04 7.78 7.31 8.12 9.17 10.26 7.82 8.24 8.15 7.87
Operating CF per Share
1.67 2.80 2.42 2.62 0.92 0.58 0.30 (0.12) 0.37 0.78
Capex per Share
(0.95) (0.62) (0.32) (0.20) (0.11) (0.36) (0.51) (0.37) (0.53) (0.43)
Free Cash Flow per Share
0.71 2.18 2.10 2.42 0.80 0.23 (0.21) (0.49) (0.16) 0.35
Cash per Share
8.50 10.79 11.01 13.10 6.91 6.55 5.93 4.69 3.78 4.01
Shareholders Equity per Share
15.17 18.08 18.25 20.42 19.15 19.94 19.61 14.48 10.46 10.01
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
15.17 18.08 18.25 20.42 19.15 19.94 19.61 14.48 10.46 10.01
Free Cash Flow
10.43 31.83 30.26 34.18 11.44 3.25 (3.08) (7.21) (2.33) 4.96
Working Capital
161.64 193.25 191.65 218.03 140.52 138.73 141.63 132.25 90.35 81.45
Capital Expenditures
(14.01) (8.98) (4.66) (2.83) (1.63) (5.14) (7.49) (5.43) (7.73) (6.23)
Net Current Asset Value
152.97 187.20 187.56 191.97 84.18 108.08 105.98 104.94 64.90 56.55
EV/EBIT
12.07 14.06 15.01 16.60 0.00 170.78 100.25 341.66 0.00 0.00
Capex to Sales
0.14 0.08 0.04 0.02 0.01 0.03 0.07 0.04 0.06 0.06
Price to Operating Income
14.54 17.50 22.32 21.38 0.00 197.32 116.96 393.49 0.00 0.00
Other line items
Depreciation/Fixed assets
0.07 0.08 0.10 0.12 1.33 0.45 0.30 2.04 0.27 0.14
Cash ROIC
3.00% 7.57% 7.16% 7.22% 3.09% 0.85% (0.83%) (2.57%) (1.11%) 2.47%
Accounts Receivable Turnover
4.20 4.41 4.73 5.23 5.53 5.48 3.53 3.96 4.80 4.77
Accounts Payable Turnover
4.53 6.05 6.33 8.24 9.59 7.81 4.86 5.01 7.44 8.41
Inventory Turnover
1.55 1.44 1.44 1.33 1.80 1.58 1.07 1.19 1.82 2.30
Average Days of Payables
34.99 90.00 36.68 48.65 53.38 42.96 81.56 59.09 46.69 44.99
Days of Inventory on Hand
242.80 293.92 248.55 279.27 274.56 202.67 357.43 233.04 197.92 139.91
Average Receivables
24.63 25.71 22.30 21.93 23.59 26.97 32.24 30.49 24.98 23.64
Average Payables
5.30 4.53 4.95 3.49 6.41 8.31 8.35 7.63 5.91 5.83
Average Inventory
15.46 19.01 21.67 21.65 34.10 41.11 37.89 32.10 24.12 21.30
Average Assets
238.00 261.43 280.81 304.85 348.16 356.57 348.33 309.88 236.69 196.51
Average Common Equity
216.81 243.13 263.55 276.00 280.39 279.74 286.32 248.91 183.13 148.73

Fold the line items

Columns are period end dates